Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9.
Rodriguez E, Boelaars K, Brown K, Eveline Li RJ, Kruijssen L, Bruijns SCM, van Ee T, Schetters STT, Crommentuijn MHW, van der Horst JC, van Grieken NCT, van Vliet SJ, Kazemier G, Giovannetti E, Garcia-Vallejo JJ, van Kooyk Y. · 2021
Read Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. by Rodriguez E, Boelaars K, Brown K, Eveline Li RJ, Kruijssen L, Bruijns SCM, van Ee T, Schetters STT, Crommentuijn MHW, van der Horst JC, van Grieken NCT, van Vliet SJ, Kazemier G, Giovannetti E, Garcia-Vallejo JJ, van Kooyk Y. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7904912.txt.
Introduction
Rodriguez and co-authors report a laboratory study of how pancreatic cancer shapes immune cells. Pancreatic ductal adenocarcinoma is hard to treat and often resists immune attack. Its cells carry extra sialic acids on their surface. Those sugars can bind Siglec receptors on immune cells and quiet them. The team tested that link.
Two enzymes, ST3GAL1 and ST3GAL4, built most of the sugar ligands in the tumour cells. Data from human tumours pointed to monocyte-derived macrophages as a group tied to poor outcomes. In lab tests, tumour sialic acids pushed monocytes to become macrophages through Siglec-7 and Siglec-9. Triggering Siglec-9 cut inflammatory output and raised PD-L1 and IL-10. The authors present the sugar pathway as a new target for immune therapy in this cancer.
Catalog record
| CREATOR | Rodriguez E, Boelaars K, Brown K, Eveline Li RJ, Kruijssen L, Bruijns SCM, van Ee T, Schetters STT, Crommentuijn MHW, van der Horst JC, van Grieken NCT, van Vliet SJ, Kazemier G, Giovannetti E, Garcia-Vallejo JJ, van Kooyk Y. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 72 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9 By Ernesto Rodriguez, Kelly Boelaars, Kari Brown, R J Eveline Li, Laura Kruijssen, Sven C M Bruijns, Thomas van Ee, Sjoerd T T Schetters, Matheus H W Crommentuijn, Joost C van der Horst, Nicole C T van Grieken, Sandra J van Vliet Published in: Nature Communications DOI: 10.1038/s41467-021-21550-4 ABSTRACT Abstract Changes in glycosylation during tumour progression are a key hallmark of cancer. One of the glycan moieties generally overexpressed in cancer are sialic acids, which can induce immunomodulatory properties via binding to Siglec receptors. We here show that Pancreatic Ductal Adenocarcinoma (PDAC) tumour cells present an increased sialylation that can be recognized by Siglec-7 and Siglec-9 on myeloid cells. We identified the expression of the α2,3 sialyltransferases ST3GAL1 and ST3GAL4 as main contributor to the synthesis of ligands for Siglec-7 and Siglec-9 in tumour cells. Analysing the myeloid composition in PDAC, using single cell and bulk transcriptomics data, we identified monocyte-derived macrophages as contributors to the poor clinical outcome. Tumour-derived sialic acids dictate monocyte to macrophage differentiation via signalling through Siglec-7 and Siglec-9. Moreover, triggering of Siglec-9 in macrophages reduce inflammatory programmes, while increasing PD-L1 and IL-10 expression, illustrating that sialic acids modulate different myeloid cells. This work highlights a critical role for sialylated glycans in controlling immune suppression and provides new potential targets for cancer immunotherapy in PDAC. Subject terms: Glycobiology, Pancreatic cancer INTRODUCTION Pancreatic ductal adenocarcinoma (PDAC) remains one of the most severe cancer types with a 5-year survival of 9%1. PDAC is characterised by early invasion to adjacent tissue and metastasis that hampers the possibility for surgical resection of the tumour, which is the only potentially curative treatment for PDAC patients2. Other therapies such as chemotherapy, targeted therapy and immunotherapy fail to improve survival of patients, which is mainly attributed to the aggressive and complex tumour microenvironment (TME)3. In order to find new treatment targets for PDAC, identification of novel immune suppressive networks in the TME is urgently needed. The PDAC TME is characterised by dense fibrotic stroma and suppressive immune cells, mostly of the myeloid lineage with only few CD8+ T cells3. The myeloid compartment is composed of a heterogeneous and multifaceted group of cells that can have different impact on tumour progression. For example, dendritic cells (DCs) can activate anti-tumour cytotoxic T cells to restrain tumour growth, while some types of macrophages and immature myeloid cells can promote tumour progression and immune evasion4. Macrophages are generally chronically polarised in the TME to have tumour-promoting properties and are referred to as tumour-associated macrophages (TAMs). Polarisation of TAMs goes beyond the M1/M2 paradigm as they express markers of both inflammatory M1 macrophages (HLA-DR) and tissue repair M2 macrophages (CD206, CD163) and are also functionally involved in both inflammation and tissue remodelling5,6. Both TAMs and DCs in the TME can originate from infiltrating monocytes7,8. Yet, little is known on the factors that determine the local differentiation of infiltrating monocytes to TAMs or DCs. It is well established that tumours present an altered glycosylation machinery that facilitates tumour progression9. Glycosylation is a posttranslational process that occurs in the endoplasmic reticulum (ER) and Golgi apparatus during the biosynthesis and transportation of proteins and lipids to the cell membrane10. In this process, monosaccharides are added in a stepwise manner to the carrier on proteins or lipids, which is regulated by the local presence or absence of glycosyltransferases, glycosidases and sugar donors10. These glycans can be sensed by immune cells via glycan binding receptors called lectins. Increasing evidence illustrates that tumour cells alter their glycosylation patterns and overexpress ‘self-associated patterns’ that trigger immune-inhibiting lectin receptors9. The changes in glycosylation during the development of PDAC, which we define as glyco-code, are not fully defined. PDAC patients have elevated levels of the serum marker CA19-9, corresponding to Sialyl LewisA, which is currently used as disease biomarker in diagnostics11. Other described glycosylation-related changes in PDAC are upregulation of sialyl LewisX, truncated O-glycans, galectin-1 and galectin-3, specific proteoglycans and increased branched and fucosylated N-glycans, which are all associated with distinct aspects of tumour progression such as tumour cell proliferation, invasion, metastasis, inflammation and angiogenesis12. However, their link to immune cell function in PDAC is unknown. Enhanced sialylation (hypersialylation) is frequently observed in solid tumours13. Sialic acids can be recognised by a family of receptors called Siglecs (Sialic acid-binding immunoglobulin-type lectins), most of which possess an immunoreceptor tyrosine-based inhibitory motif (ITIM)14. Upon engagement with Siglec receptors, sialylated glycans can trigger tolerogenic programs in different immune cell types, such as T cells, NK cells and monocytes14. In mouse models, the presence of sialic acids on tumour cells has been associated with the induction of regulatory T cells (Tregs) and a reduction in effector T cells, and increased tumour growth15. By binding DCs, sialylated antigens have also been shown to induce a regulatory phenotype by promoting IL-10 secretion and Treg induction, illustrating that tolerizing pathways are induced upon binding of sialic acids16. However, still little is known on how local sialic acid expression connects to Siglec expression and the induction of tolerogenic programs on immune cells in the PDAC TME. In this paper, we show that PDAC tumour cells present increased sialylation that is sensed by the myeloid receptors Siglec-7 and Siglec-9, contributing to the differentiation of monocytes into macrophages with an immune-suppressive phenotype. In conclusion, we find a link between the presence of sialic acids in the TME that modulate monocyte and macrophage behaviour, associated with worse clinical outcomes. RESULTS PDAC tumour cells show enhanced expression of α2,3 linked sialic acids Sialic acid metabolism involves a series of enzymes responsible for the synthesis of CMP-sialic acid, which is the donor later used by different sialyltransferases to add sialic acids to an extending glycan structure (Fig. 1A). These glycoconjugates can present sialic acids in different linkages with respect to the underlying glycan (namely α2,3, α2,6 and α2,8), each of which are catalysed by specific enzymes (Fig. 1A)14. [Figure: Sialylation is increased in pancreatic ductal adenocarcinoma (PDAC).A Representation of the different pathways that contribute to sialylation of glycans. B Gene set enrichment analysis of the pathways described in (A) in normal and tumour tissue. ΔGSVA score was calculated as the difference between the GSVA score in tumour and in normal tissue. C Immunohistochemistry analysis of the expression of sialylated glycans in normal and tumour tissue, using plant lectins specific for α2,3 (MAL I and MAL II) and α2,6 sialic acid (SNA). Data presented as mean values ± SEM. D–E Evaluation of sialic acid expression in PDAC cell lines by (D) ELISA and (E) flow cytometry. ΔD.O. at 450 nm was calculated as the difference of the O.D at 450 nm of the sample and the one of the uncoated control.] To characterise changes that occur in the sialylation machinery of PDAC, we analysed publicly available transcriptomic data that contained samples of both PDAC and normal or adjacent normal tissue (Supplementary Table 1)17–20. To investigate which specific sialylation pathways are differentially expressed between tumour and normal tissue, we used gene set enrichment analysis and differential gene expression (Fig. 1B, Supplementary Fig. 1A). We found that the sialic acid-donor synthesis pathway is particularly upregulated in